Sai Life Sciences credit ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025
95.195.1129
−62.7−62.7−335
0.04×0.04×0.06×
−0.03×−0.03×−0.16×
0.15×0.15×0.32×
−0.10×−0.10×−0.83×
11.83×11.83×3.51×
3.7%3.7%5.7%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

SAILIFE₹1,495.70

Sai Life Sciences Ltd.

· Pharma & Health
₹ CrorePeersSYNGENEDIVISLABPPLPHARMANHNEULANDLABNATCOPHARMLALPATHLABCOHANCEMcap ₹31,676 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Total Debt128.695.195.1
Net Debt-335.2-62.7-62.7
Total Debt/Equity0.060.040.04
Net Debt/Equity-0.16-0.03-0.03
Total Debt/EBITDA0.320.150.15
Net Debt/EBITDA-0.83-0.10-0.10
Interest Coverage (EBIT/Interest)3.5111.8311.83
Total Debt/Total Capital %5.703.693.69
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.